TrialClinical cardiology2017

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Robert P Giugliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.